Sec. 3. Liver cancer and disease research
333 words·~2 min read·
/bill/117/s/3041/is/section-3·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Subpart 1 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285 et seq. ) is amended by adding at the end the following new section: The Director of the Institute shall expand, intensify, and coordinate the activities of the Institute with respect to research on liver cancer and other liver diseases. In carrying out subsection (a), the Director of the Institute shall provide for an expansion and intensification of the conduct and support of— basic research concerning the etiology and causes of liver cancer; clinical research and related activities concerning the causes, prevention, detection, and treatment of liver cancer; control programs with respect to liver cancer, in accordance with section 412, including community-based programs designed to assist members of medically underserved populations (including women), low-income populations, or minority groups; and information and education programs with respect to liver cancer, in accordance with section 413.
The Director of the Institute shall establish an inter-institute working group to coordinate research agendas focused on finding treatments and cures for liver cancer and other liver diseases, including hepatitis B and nonalcoholic steatohepatitis. The Secretary may award grants and enter into cooperative agreements with entities for the purpose of expanding, conducting, and supporting research on— conditions known to increase an individual’s risk of developing a major liver disease, such as liver cancer, hepatitis B, hepatitis C, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis of the liver; and early detection and diagnostic measures for such a disease, including the study of molecular pathology and biomarkers for early detection.
In the case of an entity that is a hospital or a health care facility, the Secretary may award a grant or enter into a cooperative agreement with such an entity for the purpose of supporting an experimental treatment or prevention program for liver cancer carried out by such entity. For purposes of carrying out this subsection, there is authorized to be appropriated $45,000,000 for each of fiscal years 2023 through 2027. .
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 3
Liver cancer and disease research
Cites 1Cited by 0 across 0 sources